Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Foundation Nationale De Transfusion Sanguine

Laboratorie Francais Du Fractionnement Et Des Biotechnologies

Laboratoire Francais Du Fractionnement Et Des Biotechnologies Societe Anonyme

Annie Bardat

Roland Schmitthaeusler

Cornelius Pompe

Edith Begin

Sami Chtourou

Nassirah Khandoudi

Olivier Just

Roland Schmitthauesler

A stable pharmaceutical composition in liquid form or in solid form, containing factor VII. The composition is free of mannitol, sucrose, and any antioxidant.

Factor VII composition

This invention is related to a stabilizing formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilization of immunoglobulins G compositions in liquid form and in lyophilized form. The invention also relates to an immunoglobulins G composition in liquid form or in lyophilized form comprising said stabilizing formulation.

Method for stabilising an immunoglobulin G composition in liquid form

The invention relates to a stable pharmaceutical composition in liquid form or in solid form, comprising factor VII, said composition being free of mannitol and of sucrose, or even also of any antioxidant.

Stabilising formulation for immunoglobulin G compositions in liquid form and in lyophilised form

The invention relates to a method of viral inactivation by dry heating of a virus present or potentially present in a biological product that has been dried according to the glass transition temperature.

Invention relates to a method of viral inactivation by dry heating

The invention relates to a method for obtaining cryoprecipitatable proteins, comprising a viral inactivation step by thermally treating a lyophilisate of these proteins, comprising, before rendering the proteins in the form of a lyophilisate, an initial addition step, to these proteins, of a stabilizing and solubilizing formulation containing a mixture consisting of arginine, at least one hydrophobic amino acid and of tribasic sodium citrate. The invention also relates to a concentrate consisting of at least one cryoprecipitable protein containing the stabilizing and solubilizing formulation introduced according to the method and being suited for therapeutic use.

Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment

The invention discloses a lyophilized pharmaceutical composition designed to imitate a medicinal product containing proteins or peptides, free of medicinal product, and is capable of being used as a placebo, characterized in that the composition comprises an excipient for the medicinal product, one or more alcohol-sugars on crystalline form and/or one or more amino acids in crystalline form. The composition has osmolarity ranging between 250 and 650 milliosmoles after being restored in the form of solution. The pharmaceutical composition can be used for injection or for percutaneous or ocular application.

Freeze-dried placebo pharmaceutical composition designed to imitate a medicine, in particular based on proteins or polypeptides

A method is described for decontaminating or sterilizing a vacuum sealed container, particularly after a lyophilization cycle, wherein one or a plurality of containers containing microorganisms or dangerous products by introducing an aqueous gas or liquid into the container after dehydration. Also described is a device for performing the method.

Growing community of inventors

Limours, France

Annie Bardat